Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist,

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 pounds, or about 7.9% of their body weight.